UK-based digital health solutions provider Medopad has acquired US artificial intelligence (AI) startup Sherbit in order to enhance healthcare for patients suffering from chronic diseases.

Established in 2014, Sherbit offers data-driven technology solutions to help healthcare providers improve patient care by delivering personalised insights and recommendations.

The acquisition is intended to complement Medopad’s health technology and support its strategy to advance the healthtech ecosystem.

Medopad’s technology provides doctors with information about patients outside the hospital in real-time. This is said to improve treatment, save time and give patients more control over the disease management.

The company collaborates with healthcare organisations such as pharma companies, research institutes, insurers and technology companies to address patient monitoring challenges for rare, chronic and complex diseases.

Medopad CEO and founder Dan Vahdat said: “Acquiring Sherbit fits within our strategy to bring the healthtech ecosystem closer together, and to realise our vision to create a world where people can live longer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Sherbit has a strong track record of success working with some of the most prestigious healthcare organisations in the US, including the Mayo Clinic, Tufts Medical Center and Jefferson Health.

“Through this acquisition, Medopad will provide its technology to support solutions across different disease areas from rare diseases to chronic conditions.”

“Through this acquisition, Medopad will provide its technology to support solutions across different disease areas from rare diseases to chronic conditions, reducing fragmentation and delivering at scale for Sherbit’s current and pipeline clients.”

The deal is part of Medopad’s expansion in the US, and is the first amongst its planned acquisitions.

In January this year, the company formed an alliance with US’ Johns Hopkins to leverage machine learning and patient monitoring solutions for providing better heathcare solutions.

Apart from the US market, Medopad is also boosting its footprint in China and Europe. The company previously signed various Chinese deals worth more than $140m.